Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease

Abstract

There is an unmet clinical need for pharmacologic treatment for metabolic dysfunction-associated steatotic liver disease (MASLD). Hepatocyte cell death is a hallmark of this highly prevalent chronic liver disease, but the dominant type of cell death remains uncertain. Here we report that ferroptosis, an iron-catalyzed mode of regulated cell death, contributes to MASLD. Unsupervised clustering in a cohort of biopsy-proven MASLD patients revealed a subgroup with hepatic ferroptosis signature and lower glutathione peroxidase 4 (GPX4) levels. Likewise, a subgroup with reduced ferroptosis defenses

Abstract by Cédric Peleman; Stig Hellemans; Geraldine Veeckmans; Wout Arras; Hao Zheng; Ine Koeken; Emily Van San; Behrouz Hassannia, Cell Death and Differentiation (2024) — licensed CC BY 4.0.

Related failures